Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

The purpose of this study is to compare any good/bad effects patients may have when treated with standard treatment against patients who are treated with standard treatment plus erlotinib. You are being asked to take part in this research study because you have early stage non-small cell lung cancer that was surgically removed and may have been treated with chemotherapy and/or radiation. The tumor removed has a mutation of a gene called EGFR.


This research study is led by Dr. John McCann.

Contact: Dawn DeMarinis, 413-794-4362

Participation details:

August 18, 2014
Cancer, Cancer - Lung

D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA

Completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.
Interventional (Clinical Trial), Randomized